Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Monotherapy and Combination Therapy in Adult Participants With Hepatic Impairment

Next Previous
X
Search
Trial Profile

A Phase 1 Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Monotherapy and Combination Therapy in Adult Participants With Hepatic Impairment

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elebsiran (Primary) ; Tobevibart (Primary)
  • Indications Hepatitis B; Hepatitis D
  • Focus Pharmacokinetics
  • Sponsors Vir Biotechnology

    • Most Recent Events

    • 01 May 2024 Planned End Date changed from 1 Mar 2024 to 30 Apr 2027.
    • 01 May 2024 Planned primary completion date changed from 1 Sep 2023 to 25 Sep 2026.
    • 14 Nov 2023 Results assessing the pharmacokinetics and safety of VIR-2218 in cirrhotic participants who have hepatic impairment with Childs-Pugh-Turcotte Class-B score, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top